Incidence and Prevalence of Pain Medication Prescriptions in Pathologies with a Potential for Chronic Pain
Authors:
- 8 December 2023
- journal article
- research article
- Published by Wolters Kluwer Health in Anesthesiology
- Vol. 140 (3) , 524-537
Abstract
Background: Heightened risks of dependence, addiction, anxiolytic effects, or prescription overdose death due to long-term use of pain medication have increased awareness about extended pain medication use in chronic pain populations. The goal of this study was to evaluate the incidence and prevalence of pain medication prescriptions from 2012 to 2022 in common pathologies with a potential for chronic pain. Methods: A retrospective cohort study was conducted using electronic health records from TriNetX (Cambridge, Massachusetts) Global Collaborative Network. For 10 distinct cohorts (total n = 9,357,584 patients), pain medication prescriptions were extracted for five classes, namely nonsteroidal anti-inflammatory drug (NSAIDs) and acetaminophen, opioids, gabapentinoids, neuropathic mood agents, and muscle relaxants. Annual incidence and prevalence of each class of medication were evaluated for the past 11 yr. Results: From 2012 to 2022, there was a significant increase in prescriptions of NSAIDs, except for patients with fibromyalgia, and persistent spinal pain syndrome (PSPS) type 2. Interestingly, over time, prescriptions of opioids in patients with complex regional pain syndrome, endometriosis, osteoarthritis, and PSPS type 2 increased, as did prescriptions of muscle relaxants for all cohorts except those with fibromyalgia. Incidence of prescriptions of neuropathic mood agents is high for patients with complex regional pain syndrome (both types) and PSPS type 2. Only for benzodiazepines did there seem to be a decline over the years, with a significantly decreased time trend in patients with complex regional pain syndrome type 1, fibromyalgia, and PSPS type 2. Conclusions: During the last 11 yr, an increase in incidence of NSAIDs and acetaminophen, opioids, neuropathic agents, and muscle relaxants was observed. Only prescriptions of benzodiazepines significantly decreased over time in specific cohorts. Overall, patients with PSPS type 2 and complex regional pain syndrome (both types) consume a broad variety of pain medication classes. Editor’s Perspective: What We Already Know about This Topic: What This Article Tells Us That Is New:Keywords
This publication has 40 references indexed in Scilit:
- A Decade of Gabapentinoid Misuse: An Analysis of the European Medicines Agency’s ‘Suspected Adverse Drug Reactions’ DatabaseCNS Drugs, 2016
- CDC Guideline for Prescribing Opioids for Chronic Pain — United States, 2016MMWR. Recommendations and Reports, 2016
- Prevalence and determinants of medication non‐adherence in chronic pain patients: a systematic reviewActa Anaesthesiologica Scandinavica, 2016
- Substance misuse of gabapentinBritish Journal of General Practice, 2012
- Medication Quantification Scale Version III: Internal Validation of Detriment Weights Using a Chronic Pain PopulationPain Practice, 2008
- Pharmacologic therapies for complex regional pain syndromeCurrent Pain and Headache Reports, 2007
- Medication Quantification Scale Version III: Update in Medication Classes and Revised Detriment Weights by Survey of American Pain Society PhysiciansThe Journal of Pain, 2005
- Variations in Patients’ Adherence to Medical RecommendationsMedical Care, 2004
- A modified Mann-Kendall trend test for autocorrelated dataJournal of Hydrology, 1998
- Nonparametric Tests Against TrendEconometrica, 1945